Tuesday, November 12, 2013 Join us for an update on the HSG First-HD clinical trial with incredible special guests Jody Goldstein from Rochester and Greg Suter from the HNDC.   First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. For more information about First-HD you can contact the HSG directly: Toll-free number:  (800) 487-7671  (North America) OR email: info@hsglimited.org Visit: www.ClinicalTrials.gov